Brief: JHBP CY Says Obtained Investigational New Drug Approval From National Medical Products Administration
June 6 (Reuters) - Genor Biopharma Holdings Ltd 6998.HK :
* OBTAINED INVESTIGATIONAL NEW DRUG APPROVAL FROM NATIONAL
MEDICAL
PRODUCTS ADMINISTRATION FOR PHASE I/II CLINICAL TRIALS OF GB263T
Source text for Eikon: ID:nHKS3qhrxB
Further company coverage: 6998.HK
Recent news on Edding Genor group
See all newsBrief: JHBP CY Says Chairman And CEO Ni Xin To Buy Shares Up To USD 1 Million From Aug 31, 2026
Brief: Edding Genor Group Expects Revenue Of RMB850 MLN-RMB900 MLN For HY
Brief: Jhbp Cy Disposal Of Equity Interest In Candid Therapeutics
Edding Genor climbs on approval of clinical trial of cancer drug in China
Brief: JHBP CY's Phase Ib/Ii Clinical Trial Of Gb268 Obtains IND Approval By NMPA